IP Library › Granted Patent US 12,543,711
Granted Patent B2
US 12,543,711 · App. 17/545,099 · Granted Feb 10, 2026

Non-human animals expressing pH-sensitive immunoglobulin sequences

Inventors: John McWhirter (Greenville, NC); Lynn Macdonald (Harrison, NY); Joel H. Martin (Putnam Valley, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc
A01K67/0275A01K67/0278C07K16/00C12N15/8509A01K2217/072A01K2217/075A01K2217/15A01K2227/105A01K2267/01C07K2317/10C07K2317/21C07K2317/92C07K2317/94C12N2800/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,543,711
App. No.
17/545,099
Granted
Feb 10, 2026
Kind
B2
Abstract

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.

Claims (55)

1 . A method of obtaining a lymphocyte that expresses an antigen-specific immunoglobulin variable domain with histidines encoded by germline histidine codons, comprising

harvesting the lymphocyte from a non-human animal,

wherein the non-human animal comprises in its germline genome either or both

(i) at an endogenous immunoglobulin heavy chain locus, an unrearranged immunoglobulin heavy chain variable region gene sequence comprising an unrearranged human V H gene segment, an unrearranged D H gene segment, and an unrearranged human J H gene segment operably linked to an immunoglobulin heavy chain constant region gene sequence, wherein one or more of the unrearranged human V H , unrearranged D H , and unrearranged human J H gene segments comprise, in a complementarity determining region 3 (CDR3) encoding sequence, a substitution of at least one non-histidine codon with a histidine codon or an insertion of at least one histidine codon and

(ii) at an endogenous immunoglobulin light chain locus, an unrearranged human immunoglobulin light chain variable region gene sequence comprising unrearranged human V L and unrearranged human J L gene segments operably linked to an endogenous immunoglobulin light chain constant region gene sequence, wherein one or more of the unrearranged human V L and J L gene segments comprise, in a CDR3 encoding sequence, a substitution of at least one non-histidine codon with a histidine codon or an insertion of at least one histidine codon;

wherein the non-human animal further comprises in vivo a diverse repertoire of antibodies that bind an antigen of interest, wherein each of the diverse repertoire of antibodies comprises

(a) an immunoglobulin heavy chain variable domain that retains, in a CDR3, at least one histidine amino acid encoded by the substituted or inserted histidine codon in the germline genome and/or

(b) an immunoglobulin light chain variable domain that retains, in a CDR3, at least one histidine amino acid encoded by the substituted or inserted histidine codon in the germline genome; and

wherein the lymphocyte expresses one of the diverse repertoire of antibodies.

2 . The method of claim 1 , wherein the unrearranged D H gene segment comprises a synthetic D segment.

3 . The method of claim 1 , wherein the unrearranged human D H gene segment comprises an inverted human D H segment.

4 . The method of claim 1 , wherein an endogenous non-human immunoglobulin heavy chain variable region gene sequence is replaced with the unrearranged immunoglobulin heavy chain variable region gene sequence such that the unrearranged immunoglobulin heavy chain variable region gene sequence is operably linked to an endogenous non-human immunoglobulin heavy chain constant region gene sequence, and/or

wherein an endogenous non-human immunoglobulin light chain variable region gene sequence is replaced with the unrearranged human immunoglobulin light chain variable region gene-sequence such that the unrearranged human immunoglobulin light chain variable region gene sequence is operably linked to an endogenous non-human immunoglobulin light chain constant region gene sequence.

5 . The method of claim 1 , wherein the unrearranged immunoglobulin heavy chain variable region gene sequence and/or the unrearranged human immunoglobulin light chain variable region gene sequence further comprises a substituted or inserted histidine codon in a CDR1 encoding sequence, a CDR2 encoding sequence, and/or an N terminal encoding sequence or a loop encoding sequence.

6 . The method of claim 1 , wherein the non-human animal is a rat, a mouse, or a hamster.

7 . The method of claim 1 , further comprising a step of producing a hybridoma from the harvested lymphocyte.

8 . A hybridoma produced according to the method of claim 7 .

9 . The method of claim 1 , further comprising

obtaining from the harvested lymphocyte, or a hybridoma produced therefrom,

a first nucleotide sequence that encodes the immunoglobulin heavy chain variable domain that retains at least one histidine amino acid encoded by the substituted or inserted histidine codon in the germline genome and/or

a second nucleotide sequence that encodes the immunoglobulin light chain variable domain that retains at least one histidine amino acid encoded by the substituted or inserted histidine codon in the germline genome; and

expressing in a cell a first nucleic acid operably linked to a human heavy chain constant region gene sequence and/or a second nucleic acid operably linked to a human light chain constant region gene sequence,

wherein the first nucleic acid comprises a sequence identical to the first nucleotide sequence, and

wherein the second nucleic acid comprises a sequence identical to the second nucleotide sequence.

10 . A nucleic acid comprising a sequence identical to the first nucleotide sequence or the second nucleotide sequence obtained according to the method of claim 9 .

11 . A cell comprising the nucleic acid of claim 10 .

12 . An immunoglobulin variable domain made by the lymphocyte obtained by the method of claim 1 .

13 . A method of obtaining a lymphocyte that expresses an antigen-specific immunoglobulin variable domain with histidines encoded by germline histidine codons, comprising

harvesting the lymphocyte from a non-human animal;

wherein the non-human animal comprises in its germline genome both

(i) at an endogenous immunoglobulin heavy chain locus, an unrearranged human immunoglobulin heavy chain variable region gene sequence comprising

unrearranged human V H , unrearranged human D H , and unrearranged human J H gene segments operably linked to an immunoglobulin heavy chain constant region gene sequence, wherein one or more of the unrearranged human V H , unrearranged human D H , and unrearranged human J H gene segments comprise, in a CDR3 encoding sequence, a substitution of at least one non-histidine codon with a histidine codon or an insertion of at least one histidine codon, and

(ii) at an endogenous immunoglobulin light chain locus, a rearranged human immunoglobulin light chain variable region gene sequence comprising a human V L gene segment rearranged with a human J L gene segment operably linked to an endogenous immunoglobulin light chain constant region gene sequence, wherein the rearranged human immunoglobulin light chain variable region gene sequence comprises, in a CDR3 encoding sequence, a substitution of at least one non-histidine codon with a histidine codon or an insertion of at least one histidine codon;

wherein the non-human animal further comprises in vivo a diverse repertoire of antibodies that bind an antigen of interest, wherein each of the diverse repertoire of antibodies comprises

an immunoglobulin light chain variable domain that is encoded by the rearranged human immunoglobulin light chain variable region gene sequence, wherein the immunoglobulin light chain variable domain retains, in a CDR3, at least one histidine amino acid encoded by the substituted or inserted histidine codon in the germline genome; and

wherein the lymphocyte expresses one of the diverse repertoire of antibodies.

14 . The method of claim 13 , wherein an endogenous non-human immunoglobulin heavy chain variable region gene is replaced with the unrearranged human immunoglobulin heavy chain variable region gene sequence such that the unrearranged human immunoglobulin heavy chain variable region gene sequence is operably linked to an endogenous non-human immunoglobulin heavy chain constant region gene sequence, and

wherein an endogenous non-human immunoglobulin light chain variable region gene is replaced with the rearranged human immunoglobulin light chain variable region gene sequence such that the rearranged human immunoglobulin light chain variable region gene sequence is operably linked to an endogenous non-human immunoglobulin light chain constant region gene sequence.

15 . The method of claim 13 , wherein the rearranged human immunoglobulin light chain variable region gene sequence comprises a rearranged human Vκ1-39 gene segment or a rearranged human Vκ3-20 gene segment.

16 . The method of claim 13 , wherein the unrearranged human immunoglobulin heavy chain variable region gene sequence and/or the rearranged human immunoglobulin light chain variable region gene sequence further comprises a substituted or inserted histidine codon in a CDR1 encoding sequence, a CDR2 encoding sequence, and/or an N terminal encoding sequence or a loop encoding sequence.

17 . The method of claim 13 , wherein the non-human animal is a rat, a mouse, or a hamster.

18 . The method of claim 13 , further comprising a step of producing a hybridoma from the harvested lymphocyte.

19 . A hybridoma formed according to the method of claim 18 .

20 . The method of claim 13 , further comprising

obtaining from the harvested lymphocyte, or a hybridoma produced therefrom, a first nucleotide sequence that encodes the immunoglobulin heavy chain variable domain that is cognate to the immunoglobulin light chain variable domain, and the immunoglobulin heavy chain variable domain comprises at least one histidine amino acid that is encoded by the substituted or inserted histidine codon in the germline; and

expressing in a cell a first nucleic acid operably linked to a human heavy chain constant region gene sequence and a second nucleic acid operably linked to a human light chain constant region gene sequence,

wherein the first nucleic acid comprises a sequence identical to the first nucleotide sequence, and

wherein the second nucleic acid comprises a sequence identical to the rearranged human immunoglobulin light chain variable region gene sequence.

21 . The method of claim 20 , wherein the cell further comprises a third nucleic acid operably linked to a human heavy chain constant region gene sequence, wherein the third nucleic acid encodes a different immunoglobulin heavy chain variable domain that is cognate to the immunoglobulin light chain variable domain, and wherein the cell expresses the first, second and third nucleic acids as a bi-specific antibody.

22 . The method of claim 21 , wherein one of the human heavy chain constant region genes is modified to omit a Protein A-binding determinant.

23 . A nucleic acid comprising a sequence identical to the first nucleotide sequence obtained according to the method of claim 20 .

24 . A cell comprising the nucleic acid of claim 23 .

25 . An antigen-specific antibody made by the lymphocyte obtained according to the method of claim 13 .

26 . The method of claim 13 , wherein the unrearranged human D H gene segment comprises a synthetic D segment.

27 . The method of claim 13 , wherein the unrearranged human D H gene segment comprises an inverted human D H segment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2022
From: MCWHIRTER, JOHN; MACDONALD, LYNN; MARTIN, JOEL H.; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 058942/0220 →
Continuity (7)
Continuation 15703490 · Sep 13, 2017
Continuation 13834129 · Mar 15, 2013
Provisional Application 61736930 · Dec 13, 2012
Provisional Application 61613352 · Mar 20, 2012
Provisional Application 61612126 · Mar 16, 2012
Provisional Application 61611950 · Mar 16, 2012
Related Publication 20220217955A1 · Jul 14, 2022
References Cited (349)
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5603931A · Raso · 1997 [cited by applicant]
US 5667988A · Barbas et al. · 1997 [cited by applicant]
US 5999908A · Abelow · 1999 [cited by applicant]
US 6096551A · Barbas et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6586251B2 · Economides et al. · 2003 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6673986B1 · Kucherlapati et al. · 2004 [cited by applicant]
US 6774279B2 · Dymecki · 2004 [cited by applicant]
US 6946548B2 · Sarkar et al. · 2005 [cited by applicant]
US 7052873B2 · Tsuchiya · 2006 [cited by applicant]
US 7067284B1 · Barbas et al. · 2006 [cited by applicant]
US 7105348B2 · Murphy et al. · 2006 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7262028B2 · Van Berkel et al. · 2007 [cited by applicant]
US 7276585B2 · Lazar et al. · 2007 [cited by applicant]
US 7294754B2 · Poueymirou et al. · 2007 [cited by applicant]
US 7435871B2 · Green et al. · 2008 [cited by applicant]
US 7501552B2 · Lonberg et al. · 2009 [cited by applicant]
US 7576259B2 · Poueymirou et al. · 2009 [cited by applicant]
US 7659442B2 · Poueymirou et al. · 2010 [cited by applicant]
US 7879985B2 · Ursøet al. · 2011 [cited by applicant]
US 7910798B2 · Tanamachi et al. · 2011 [cited by applicant]
US 8062640B2 · Sleeman et al. · 2011 [cited by applicant]
US 8080243B2 · Liang et al. · 2011 [cited by applicant]
US 8158419B2 · Lonberg et al. · 2012 [cited by applicant]
US 8502018B2 · Murphy et al. · 2013 [cited by applicant]
US 8642835B2 · Macdonald et al. · 2014 [cited by applicant]
US 9301510B2 · McWhirter et al. · 2016 [cited by applicant]
US 9332742B2 · McWhirter et al. · 2016 [cited by applicant]
US 9334334B2 · McWhirter et al. · 2016 [cited by applicant]
US 9422370B2 · McWhirter et al. · 2016 [cited by applicant]
US 20020088016A1 · Bruggemann · 2002 [cited by applicant]
US 20030078385A1 · Arathoon et al. · 2003 [cited by applicant]
US 20030108925A1 · Dix et al. · 2003 [cited by applicant]
US 20040018626A1 · Murphy et al. · 2004 [cited by applicant]
US 20050170398A1 · Van Berkel et al. · 2005 [cited by applicant]
US 20060015949A1 · Lonberg et al. · 2006 [cited by applicant]
US 20060015957A1 · Lonberg et al. · 2006 [cited by applicant]
US 20060088838A1 · Murray et al. · 2006 [cited by applicant]
US 20060099207A1 · Wu et al. · 2006 [cited by applicant]
US 20060141456A1 · Edwards et al. · 2006 [cited by applicant]
US 20060199204A1 · Dix et al. · 2006 [cited by applicant]
US 20070061900A1 · Murphy et al. · 2007 [cited by applicant]
US 20070280945A1 · Stevens et al. · 2007 [cited by applicant]
US 20080069822A1 · Jensen et al. · 2008 [cited by applicant]
US 20080078000A1 · Poueymirou et al. · 2008 [cited by applicant]
US 20090035836A1 · Datta et al. · 2009 [cited by applicant]
US 20090181855A1 · Vasquez et al. · 2009 [cited by applicant]
US 20100069614A1 · Houtzager et al. · 2010 [cited by applicant]
US 20100146647A1 · Logtenberg et al. · 2010 [cited by applicant]
US 20100310586A1 · Dolcetti et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110076275A1 · Igawa et al. · 2011 [cited by applicant]
US 20110098450A1 · Igawa et al. · 2011 [cited by applicant]
US 20110111406A1 · Igawa et al. · 2011 [cited by applicant]
US 20110145937A1 · McWhirter et al. · 2011 [cited by applicant]
US 20110195454A1 · McWhirter et al. · 2011 [cited by applicant]
US 20110229489A1 · Pons et al. · 2011 [cited by applicant]
US 20120021409A1 · McWhirter et al. · 2012 [cited by applicant]
US 20120167237A1 · Bradley et al. · 2012 [cited by applicant]
US 20120192300A1 · Babb et al. · 2012 [cited by applicant]
US 20120204278A1 · Bradley et al. · 2012 [cited by applicant]
US 20120322108A1 · Macdonald et al. · 2012 [cited by applicant]
US 20130011866A1 · Igawa et al. · 2013 [cited by applicant]
US 20130045492A1 · Babb et al. · 2013 [cited by applicant]
US 20130145484A1 · Logtenberg et al. · 2013 [cited by applicant]
US 20130185821A1 · Babb et al. · 2013 [cited by applicant]
US 20130198880A1 · Babb et al. · 2013 [cited by applicant]
US 20130247234A1 · McWhirter et al. · 2013 [cited by applicant]
US 20130247235A1 · McWhirter et al. · 2013 [cited by applicant]
US 20130302836A1 · McWhirter et al. · 2013 [cited by applicant]
US 20140013456A1 · McWhirter et al. · 2014 [cited by applicant]
US 20140329711A1 · McWhirter et al. · 2014 [cited by applicant]
US 20150059009A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150119556A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150250151A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150313193A1 · McWhirter et al. · 2015 [cited by applicant]
US 20160219847A1 · McWhirter et al. · 2016 [cited by applicant]
US 20160229906A1 · McWhirter et al. · 2016 [cited by applicant]
US 20160311899A1 · McWhirter et al. · 2016 [cited by applicant]
US 20170369593A1 · McWhirter et al. · 2017 [cited by applicant]
US 20190021295A1 · Babb et al. · 2019 [cited by applicant]
US 20190029237A1 · McWhirter et al. · 2019 [cited by applicant]
US 20190040123A1 · McWhirter et al. · 2019 [cited by applicant]
US 20190071519A1 · McWhirter et al. · 2019 [cited by applicant]
US 20190077884A1 · McWhirter et al. · 2019 [cited by applicant]
US 20190090462A1 · Babb et al. · 2019 [cited by applicant]
CN 1277632A · 2000 [cited by applicant]
CN 1484707A · 2004 [cited by applicant]
CN 1560081A · 2005 [cited by applicant]
EP 1439234A1 · 2004 [cited by applicant]
EP 0843961B1 · 2007 [cited by applicant]
EP 1605058B1 · 2009 [cited by applicant]
EP 2147594A1 · 2010 [cited by applicant]
EP 2275443A1 · 2011 [cited by applicant]
EP 2505654A1 · 2012 [cited by applicant]
EP 2517556A2 · 2012 [cited by applicant]
EP 2517557A2 · 2012 [cited by applicant]
EP 2556747A2 · 2013 [cited by applicant]
EP 2564695A1 · 2013 [cited by applicant]
EP 2825036B1 · 2018 [cited by applicant]
WO 1992003918A1 · 1992 [cited by applicant]
WO 1994002602A1 · 1994 [cited by applicant]
WO 1996034096A1 · 1996 [cited by applicant]
WO 1998046645A2 · 1998 [cited by applicant]
WO 1998050431A2 · 1998 [cited by applicant]
WO 2002020767A2 · 2002 [cited by applicant]
WO 2002036789A2 · 2002 [cited by applicant]
WO 2004009618A2 · 2004 [cited by applicant]
WO 2004106375A1 · 2004 [cited by applicant]
WO 2005007696A2 · 2005 [cited by applicant]
WO 2006117699A2 · 2006 [cited by applicant]
WO 2007117410A2 · 2007 [cited by applicant]
WO 2008043822A2 · 2008 [cited by applicant]
WO 2008054606A2 · 2008 [cited by applicant]
WO 2008076379A2 · 2008 [cited by applicant]
WO 2008112922A2 · 2008 [cited by applicant]
WO 2009125825A1 · 2009 [cited by applicant]
WO 2009157771A2 · 2009 [cited by applicant]
WO 2010039900A2 · 2010 [cited by applicant]
WO 2010053751A1 · 2010 [cited by applicant]
WO 2010070263A1 · 2010 [cited by applicant]
WO 2010128897A1 · 2010 [cited by applicant]
WO 2011004192A1 · 2011 [cited by applicant]
WO 2011072204A1 · 2011 [cited by applicant]
WO 2011097603A1 · 2011 [cited by applicant]
WO 2011111007A2 · 2011 [cited by applicant]
WO 2011122011A2 · 2011 [cited by applicant]
WO 2011158009A1 · 2011 [cited by applicant]
WO 2011163314A1 · 2011 [cited by applicant]
WO 2012141798A1 · 2012 [cited by applicant]
WO 2012148873A2 · 2012 [cited by applicant]
WO 2013022782A1 · 2013 [cited by applicant]
WO 2013046722A1 · 2013 [cited by applicant]
WO 2013079953A1 · 2013 [cited by applicant]
WO 2013134263A1 · 2013 [cited by applicant]
WO 2013184761A1 · 2013 [cited by applicant]
WO 2014130690A1 · 2014 [cited by applicant]
WO 2010136598A1 · 2020 [cited by applicant]
UniPro Accession No. P01619, Human KV3-20, downloaded from https://www.uniprot.org/uniprotkb/P01619/entry#sequences on Apr. 17, 2025. [cited by examiner]
Adderson, E. et al., Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodi… [cited by applicant]
Arnold et al., (1994) “Development of B-1 cells: Segregation of Phosphatidyl Choline-specific B Cells to the B-1 Population Occurs after Immunoglobulin Gene Expression,” J. Exp. Med., 179:1585-1595. [cited by applicant]
Aucouturier et al., (1992) “Human rearranged IgK mRNA VJC region,” GenBank Accession No. M87478 1 page, first referenced Mar. 3, 1992, first seen at NCBI Apr. 27, 1993. [cited by applicant]
Aucouturier et al., (1993) “Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome,” J. Immunol., 150(8):3561-3568. [cited by applicant]
Auerbach et al., (2000) “Establishment and Chimera Analysis of 129/SvEv- and C57BL/6-Derived Mouse Embryonic Stem Cell Lines,” BioTechniques 29:1024-1032. [cited by applicant]
Basu, (1984) “Receptor-mediated endocytosis: An overview of a dynamic process,” J. Biosci. 6(4):535-542. [cited by applicant]
Bauer et al., (1988) “Structure and pre-B lymphocyte restricted expression of the VpreB gene in humans and conservation of its structure in other mammalian species,” The EMBO Journal, 7(1):111-116. [cited by applicant]
Beguinot et al., (1984) “Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes,” PNAS, 81:2384-2388. [cited by applicant]
Bostrom et al., (2009) “Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site,” Science, 323(5921):1610-1614 and supplementary pages (8 pages). [cited by applicant]
Bot et al., (1996) “V [cited by applicant]
Brevini et al., (2010) “No shortcuts to pig embryonic stem cells,” Theriogenology 74:544-550. [cited by applicant]
Brezinschek et al., (1998) “Pairing of Variable Heavy and Variable κ Chains in Individual Naïve and Memory B Cells,” J. Immunol., 160(10):4762-4767. [cited by applicant]
Brown et al., (1983) “Recycling Receptors: The Round-Trip Itinerary of Migrant Membrane Proteins,” Cell, 22:663-667. [cited by applicant]
Bruggemann (1997) “The Preparation of Human Antibodies from Mice Harbouring Human Immunoglobulin Loci,” (Edited by L. M. Houdebine) Transgenic Animals: Generation and Use, Amsterdam: Harwood Acedemic Publishers, pp. 397… [cited by applicant]
Cao et al., (2009) “Isolation and Culture of Primary Bovine Embryonic Stem Cell Colonies by a Novel Method,” Journal of Experimental Zoology, 311A:368-376. [cited by applicant]
Carmack et al., (1991) “Influence of a V κ 8 L chain transgene on endogenous rearrangements and the immune response to the HA(Sb) determinant of influenza virus,” J. Immunol., 147(6):2024-2033. [cited by applicant]
Carter, (2001) “Bispecific human IgG by design,” Journal of Immunological Methods, 248(1-2):7-15. [cited by applicant]
Cascalho et al., (1996) “A Quasi-Monoclonal Mouse,” Science, 272(5268):1649-1652. [cited by applicant]
Chaparro-Riggers et al., (2012) “Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9,” J. Biol. Chem. 287(14):11090-11097. [cited by applicant]
Chen et al., (1994) “Deletion and Editing of B Cells that Express Antibodies to DNA,” Journal of Immunology, 152:1970-1982. [cited by applicant]
Choi et al., (2004) “Characterization and comparative genomic analysis of intronless Adams with testicular gene expression,” Genomics 83(4): 636-646. [cited by applicant]
Clark et al., “Trends in Antibody Sequence Changes during the Somatic Hypermutation Process,” J. Immunol., 2006, 177:333-340. [cited by applicant]
Corbett et al., (1997) “Sequence of the Human Immunoglobulin Diversity (D) Segment Locus: A Systematic Analysis Provides No Evidence for the Use of DIR Segments, Inverted D Segments, “Minor” D Segments or D-D Recombinat… [cited by applicant]
Dall'Acqua et al., (2006) “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” J. Biol. Chem. 281:23514-23524. [cited by applicant]
Davies et al., (1993) “Creation of Mice Expressing Human Antibody Light Chains by Introduction of a Yeast Artificial Chromosome Containing the Core Region of the Human Immunoglobulin κ Locus,” Nature Biotechnology 11:91… [cited by applicant]
De Kruif et al., (2009) “Human Immunoglobulin Repertoires against Tetanus Toxoid Contain a Large and Diverse Fraction of High-Affinity Promiscuous VH Genes,” J. Mol. Biol., 387:548-558. [cited by applicant]
De Wildt et al., (1999) “Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire,” J. Mol. Biol., 285(3): 895-901. [cited by applicant]
Dechiara et al., (2009) Chapter 16: VelociMouse: Fully ES Cell-Derived FO Generation Mice Obtained from the Injection of ES Cells into 8-Cell Stage Embryos, Gene Knockout Protocols: Second Edition, vol. 530, Humana Pres… [cited by applicant]
Deng et al., (2010) “Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-a Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys, Drug Metabolism and Disposition,” 38(4):600-605. [cited by applicant]
Dennis (2002) “Welfare issues of genetically modified animals,” ILAR Journal, 43(2):100-109. [cited by applicant]
Desienhofer, (1981) “Crystallographic Refinement and Atomic Models of a Human Fc Fragment and Its Complex with Fragment B of Protein A from [cited by applicant]
Donohoe et al., (2000) “Transgenic Human 5 Rescues the Murine Lambda5 Nullizygous Phenotype,” J. Immunol., 164:5269-5276. [cited by applicant]
Dunn et al., (1989) “Iterative Fractionation of Recycling Receptors from Lysosomally Destined Ligands in an Early Sorting Endosome,” J. Cell. Biol. 109(6/2):3303-3314. [cited by applicant]
Edwards et al., (2008) “The ADAM Metalloproteinases”, Molecular Aspects of Medicine, 29(5):258-289. [cited by applicant]
Fallon et al., (2000) “Increased Endosomal Sorting of Ligand to Recycling Enhances Potency of an Interleukin-2 Analog,” J. Biol. Chem. 275(10):6790-6797. [cited by applicant]
Featherstone et al., (2010) “The Mouse Immunoglobulin Heavy Chain V-D Intergenic Sequence Contains Insulators That May Regulate Ordered V(D)J Recombination,” J. Biol. Chem., 285(13):9327-9338. [cited by applicant]
Festing et al., (1999) “Revised nomenclature for strain 129 mice,” Mammalian Genome, 10:836. [cited by applicant]
Fishwild et al., (1996) “High-avidity human IgGk monoclonal antibodies from a novel train of mililocus transgenic mice,” Nat. Biotech., 14(7):845-851. [cited by applicant]
Fraenkel et al., (2007) “Allelic ‘choice’ governs somatic hypermutation in vivo at the immunoglobulin kappa-chain locus,” Nat. Immunol., 8(7):715-722. [cited by applicant]
Gan et al., (2009) “Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery,” Traffic 10(5):600. [cited by applicant]
Gay et al., (1993) “Receptor editing: an approach by autoreactive B cells to escape tolerance,” J. Exp. Med., 177(4):999-1008. [cited by applicant]
Giallourakis et al., (2010) “Elements between the IgH variable (V) and diversity (D) clusters influence antisense transcription and lineage-specific V(D)K recombination,” PNAS, 107(51):22207-22212. [cited by applicant]
Goldstein and Brown, (2009) “The LDL Receptor,” Arterioscler. Thromb. Vasc. Biol. 29:431-438. [cited by applicant]
Goletz et al., (2002) “Selection of Large Diversities of Antiidiotypic Antibody Fragments by Phage Display”, J. Mol. Biol. 315:1087-1097. [cited by applicant]
Gonnet et al., (1992) “Exhaustive Matching of the Entire Protein Sequence Database,” Science 256:1443-1445. [cited by applicant]
Gonzalez-Fernandez et al., (1993) “Analysis of somatic hypermutation in mouse Peyer's patches using immunoglobulin κ light-chain transgenes,” PNAS, 90:9862-9866. [cited by applicant]
Goodhardt et al., (1987), “Rearrangement and Expression of rabbit immunoglobulin K light chain gene in transgenic mice,” PNAS, 84:4229-4233. [cited by applicant]
Goyenechea et al., (1996) “Modifying the sequence of an immunoglobulin V-gene alters the resulting pattern of hypermutation,” PNAS, 93:13979-13984. [cited by applicant]
Goyenechea et al., (1997) “Cells strongly expressing Ig(kappa) transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers,” EMBO J., 16(13):3987-94. [cited by applicant]
Green et al., (1994) “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,” Nat. Genet., 7(1):13-21. [cited by applicant]
Green et al., (1998) “Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes,” J. Exp. Med., 188(3):483-495. [cited by applicant]
Green et al., (1999) “Antibody engineering via geneitc engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,” J. Immunol. Methods, 231:11-23. [cited by applicant]
Han et al., 2009) “Comprehensive Analysis of Reproductive ADAMs: Relationship of ADAM4 and ADAM6; with an ADAM Complex Required for Fertilization in Mice”, Biol. Reprod., 80(5):1001-1008. [cited by applicant]
Hardy and Hayakawa, (2001) “B cell development pathways,” Annu. Rev. Immunol., 19:595-621. [cited by applicant]
Hartley and Goodnow (1993) “Censoring of self-reactive B cells with a range of receptor affinities in transgenic mice expressing heavy chains for a lysozyme-specific antibody,” International Immunology, 6(9):1417-1425. [cited by applicant]
Hendricks et al., (2010) “Organization of the variable region of the immunoglobin heavy-chain gene locus of the rat,” Immunogenetics, 62:479-486. [cited by applicant]
Hengstschlager et al., (1994) “A lambda 1 transgene under the control of a heavy chain promoter and enhancer does not undergo somatic hypermutation,” Eur. J. Immunol., 24:1649-1656. [cited by applicant]
Hochedlinger et al., (2002) “Monoclonal Mice Generated by Nuclear Transfer from Mature B and T Donor Cells,” Nature 415(6875):1035-1038. [cited by applicant]
Hoi and Ippolito (2013) Intrinsic bias and public rearrangements in the human immunoglobulin Vλ light chain repertoire, Genes and Immunity, 14:271-276. [cited by applicant]
Hömig-Hölzel et al., (2008) “Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis,” J. Exp. Med., 205(6):1317-1329. [cited by applicant]
Houdebine (2009) Methods to Generate Transgenic Animals, Genetic Engineering in Livestock, New Applications and Interdisciplinary Perspectives, Engelhard M, et al., 2009, XVI, 1 46 p. 8 illus., pp. 31-47, see p. 36. [cited by applicant]
Igawa et al., (2010) “Reduced elimination of IgG antibodies by engineering the variable region,” Protein Engineering, Design & Selection, 23(5):385-392. [cited by applicant]
Igawa et al., (2010) “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nature Biotech., 28(11):1203-1208 and supplement. [cited by applicant]
Igawa et al., (2011) “Engineering the variable region of therapeutic IgG antibodies,” mAbs, 3(3):243-252. [cited by applicant]
Inlay et al., (2002) “Essential roles of the kappa light chain intronic enhancer and 3′ enhancer in kappa rearrangement and demethylation,” Nat. Immunol., 3(5):463-468. [cited by applicant]
Ippolito, (2006) “Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production,” J. Exp. Med. 203(6):1567-1578. [cited by applicant]
Ito et al. (1992) “The His-probe method: effects of histidine residues introduced into the complementary-determining regions of antibodies on antigen-antibody interactions at different pH values,” FEBS Lett. 309(1):85-8… [cited by applicant]
Ivanov et al., (2002) on the Hydropathicity and Sequence Composition of HCDR3 are Conserved Across Evolution, The Antibodies, vol. 7, M. Zanetti and J. D. Capra, eds.Taylor & Francis Group, London, Chapter 3, pp. 43-67. [cited by applicant]
Jakobovits, (1995) “Production of fully human antibodies by transgenic mice,” Curr. Opin. Biotechnol., 6(5):561-566. [cited by applicant]
Jakobovits et al., (2007) “From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice,” Nature Biotech., 25(10):1134-1143. [cited by applicant]
Janeway's Immunobiology, (2008) Seventh Edition, Murphy, Travers and Walpot, eds., Garland Science, New York and London, Ch. 4, pp. 145-155. [cited by applicant]
Jendeberg et al., (1997) “Engineering of Fc1 and Fc3 from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A1,” Journal of Immunologial Methods, 201:25-34. [cited by applicant]
Jolly et al., (1997) “Rapid methods for the analysis of immunoglobulin gene hypermutation: application to transgenic and gene targeted mice,” Nucleic Acids Research, 25(10):1913-1919. [cited by applicant]
Kabat and Wu, (1991) “Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining reg… [cited by applicant]
Kaushik, (1990) “Stochastic pairing of heavy-chain and x light-chain variable gene families occurs in polyclonally activated B cells,” Proc. Natl. Acad. Sci. USA, 87: 4932-4936. [cited by applicant]
Kim et al., (2006) “Expression and relationship of mail reproductive ADAMs in mouse,” Biol. Reprod., 74:744-750. [cited by applicant]
Klöhn et al., (2013) “IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: Dec. 3-6, 2012,” San Diego, CA, Mabs, 5(2):1… [cited by applicant]
Klotz et al., (1996) “Somatic Hypermutation of a lambda 2 Transgene Under the Control of the lambda Enhancer or the Heavy Chain Intron Enhancer,” J. Immunol., 157:4458-4463. [cited by applicant]
Klotz et al. (1998)“Somatic Hypermutation of an Artificial Test Substrate Within an Igκ Transgene,” J. Immunol., 161:782-790. [cited by applicant]
Knappik et al. (2000) “Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,” JMB, 296:57-86. [cited by applicant]
Kong et al., (1998) “A lambda 3′ enhancer drives active and untemplated somatic hypermutation of a lambda 1 transgene,” J. Immunol., 161:294-301. [cited by applicant]
Kufer et al., (2004) “A revival of bispecific antibodies,” Trends Biotechnol. 22(5):238-244. [cited by applicant]
Lee and Owen, (2012) “The application of transgenic mice for therapeutic antibody discovery,” Methods in Mol. Biol. 901:137-148. [cited by applicant]
Lencer, et al. (2005) “A passionate kiss, then run: exocytosis and recycling of IgG by FcRn,” Trends in Cell Biol. 15(1):5-9. [cited by applicant]
Lefranc, (2000) “Nomenclature of the Human Immunoglobulin Genes,” Current Protocols in Immunology, Supplement 40, pp. A.1P.1-A.1P.37. [cited by applicant]
Lefranc et al. (2003) “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev. Comp. Immunol. 27:55-77, www.imgt.org. [cited by applicant]
Leitzgen et al., (1997) “Assembly of immunoglobulin Light Chains as a Prerequisite for Secretion,” J. Biol. Chem., 272(5):3117-3123. [cited by applicant]
Lindhofer et al., (1995) “Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas,” J. Immunol., 155:219-225. [cited by applicant]
Link and Schroeder, (2002) Clues to the etiology of autoimmune diseases through analysis of immunoglobulin genes, Arthritis Research, 4(2):80-83 (Available online http://arthritisresearch.com/content/4/2/080). [cited by applicant]
Logtenberg, (2007) “Antibody cocktails: next-generation biopharmaceuticals with improved potency,” Trends Biotechnol., 25(9):390-394. [cited by applicant]
Lonberg et al., (1994) “Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368:856-859. [cited by applicant]
Lonberg, (2005) “Human antibodies from transgenic animals,” Nature Biotech., 23(9):1117-1125. [cited by applicant]
Longo et al., (2008) “Characterization of immunoglobulin gene somatic hypermutation in the absence of activation-induced cytidine deaminase,” J. Immunol., 181(2):1299-1306. [cited by applicant]
Macdonald et al. (2006) “Velocigene Technology Extended to Humanization of Several Megabases of complex Gene Loci,” First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2006… [cited by applicant]
Maeda et al., (2002) “pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes,” J. Controlled Release, 82:71-82. [cited by applicant]
Marten Hofker , (2003) “Transgenic mouse methods and protocols,” Methods in Molecular Biology, 209:51-58. [cited by applicant]
Marvin et al., (2005) “Recombinant approaches to IgG-like bispecific antibodies,” Acta Pharmacologica Sinica, 26(6):649-658. [cited by applicant]
Meijer et al., (2006) “Isolation of Human Antibody Repertoires with Preservation of the Natural and Heavy Light Chain Pairing,” J. Mol. Biol., 358:764-772. [cited by applicant]
Mellman, (1992) “The Importance of Being Acidic: The Role of Acidfication in Intracellular Membrane Traffic,” J. Exp. Biol. 172:39-45. [cited by applicant]
Mendez et al., (1997) “Functional Transplant of Megabase Human Immunoglobulin Loci Recapitulates Human Antibody Response in Mice,” Nat. Genetics 15(2)146-156. [cited by applicant]
Merchant et al., (1998) “An efficient route to human bispecific IgG,” Nature Biotech., 16(7):677-681. [cited by applicant]
Moran, (2013) “Mouse Platforms Jostle for Slice of Humanized Antibody Market,” Nature Biotech., 3:267-268. [cited by applicant]
Murtaugh et al., (2011) “A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches,” Protein Sci. 20(9):1619-1631. [cited by applicant]
Nagle, (2007) “Regeneron helps make Sanofi VelocImmune to its “weak pipeline,”” <http://www.outsourcing-pharma.com>—Published Dec. 3, 2007. [cited by applicant]
Nakasako et al., (1999) “The pH-dependent Structural Variation of Complementarity-determining Region H3 in the Crystal Structures of the Fv Fragment from an Anti-dansyl Monoclonal Antibody,” J. Mol. Biol. 291:117-134. [cited by applicant]
Nemazee, (2006) “Receptor editing in lymphocyte development and central tolerance,” Nat. Rev. Immunol., 6(10):728-740. [cited by applicant]
News In Brief Article (2007) “Big Pharma vies for mice,” Nature Biotechnology, 25(6):613—Published Jun. 2007. [cited by applicant]
Nicholson et al., (1999) “Antibody Repertoires of Four- and Five-Feature Translocus Mice Carrying Human Immunoglobulin Heavy Chain and kappa and lambda Light Chain Yeast Artificial Chromosomes,” J. Immunol., 163:6898-69… [cited by applicant]
No Author Listed, Additional post-filing data and letter filed by the Applicant/Patentee for corresponding European application 09075279.1, now opposed patent EP 2147594 B1, 4 pages (Jun. 13, 2013). [cited by applicant]
No Author Listed, “Next generation transgenic mice for therapeutic human antibodies, Description of MeMoTM,” filed by the Applicant/Patentee in prosecution for corresponding European application 09075279.1, now opposed … [cited by applicant]
No Author Listed, (2011) Chapter 8: The Development and Survival of Lymphocytes, Janeway's Immunobiology, 8th Edition, Eds. Kenneth Murphy et al, Garland Science (ISBN: 9780815342434), whole document, in particular paqe… [cited by applicant]
O'Brien et al., (1987) “Somatic hypermutation of an immunoglobulin transgene in K mice,” Nature, 326(6111):405-409. [cited by applicant]
Orban et al., (1992) “Tissue- and site-specific DNA recombination in transgenic mice,” PNAS, 89(15):6861-6865. [cited by applicant]
Ozato, et al. “Comment on Gene Disruption Study Reveals a Nonredundant Role for TRIM21/Ro52 in NF-κB-Dependent Cytokine Expression in Fibroblasts,” The Journal of Immunology, 2009, 183:7619-7621. [cited by applicant]
Panka et al., (May 1988) “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” PNAS, 85:3080-3084. [cited by applicant]
Paris and Stout (2010) “Equine embryos and embryonic stem cells: Defining reliable markers of pluripotency,” Theriogenology 74:516-524. [cited by applicant]
Paul, (1993) Fundamental Immunology, 3rd ed., Raven Press, NY, Chapter 9, pp. 292-295. [cited by applicant]
Pelanda et al., (1996) “A prematurely Expressed Igκ Transgene, but Not VκJκ Gene Aegment Targeted into the Igκ Locus, Can Rescue B Cell Development in λ5-Deficient Mice,” Immunity, 5(3):229-239. [cited by applicant]
Petkova et al., (2006) “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Intl. Immunol. 18(12):1759-176… [cited by applicant]
Phan et al. (2003) “B Cell Receptor-independent Stimuli Trigger Immunoglobulin (Ig) Class Switch Recombination and Production of IgG Autoantibodies by Anergic Self-Reactive B Cells,” J. Exp. Med., 197(7):845-860. [cited by applicant]
Phan et al. (2005) “Altered Migration, Recruitment, and Somatic Hypermutation in the Early Response of Marginal Zone B Cells to T Cell-Dependent Antigen,” J. Immunology, 174:4567-4578. [cited by applicant]
Phan et al. (2006) “High affi nity germinal center B cells are actively selected into the plasma cell compartment,” JEM, 203(11):2419-2424. [cited by applicant]
Popov et al., (1999) “A human immunoglobulin lambda locus is similarly well expressed in mice and humans,” J. Exp. Med., 189(10):1611-1620. [cited by applicant]
Poueymirou et al., (2007) “F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses,” Nature Biotech. 25(1):91-99. [cited by applicant]
Poulsen et al., (2011) “Limits for Antibody Affinity Maturation and Repertoire Diversification in Hypervaccinated Humans,” J. Immunol., 187:4229-4235. [cited by applicant]
Prak et al., (1995) “Light chain replacement: a new model for antibody gene rearrangement,” J. Exp. Med., 182(2):541-548. [cited by applicant]
Presta, (2008) “Molecular engineering and design of therapeutic antibodies,” Curr. Opin. Immunol. 20(4):460-470. [cited by applicant]
Rabquer et al., (2005) “Immunoglobulin light chain variable region, partial [ [cited by applicant]
Raso et al., (1997) “Intracellular Targeting with Low pH-triggered Bispecific Antibodies,” J. Biol. Chem. 272(44):27623-27628. [cited by applicant]
Rickert et al., (1997) “B lymphocyte-specific, Cre-mediated mutagenesis in mice,” Nucleic Acids Res., 25(6):1317-1318. [cited by applicant]
Ritchie et al. (1984) “Allelic exclusion and control of endogenous immunologlobulin gene rearrangement in κ transgenic mice,” Nature, 312:517-520. [cited by applicant]
Roberts et al., (1990) “Isolation and Characterization of the Fc Receptor from Fetal Yolk Sac of the Rat,” J. Cell. Biol. 111:1867-1876. [cited by applicant]
Rojas et al., (2002) “Phage antibody fragments library combining a single human light chain variable region with immune mouse heavy chain variable regions,” J. Biotech., 94:287-298. [cited by applicant]
Roopenian and Sun, (2010) “Clinical Ramifications of the MHC Family Fc Receptor FcRn,” J. Clin. Immunol. 30(6):790-797. [cited by applicant]
Roopenian et al., (Sep. 2007) FcRn: the neonatal Fc receptor comes of age, Nature Rev. Immunol. 7:715-725. [cited by applicant]
Rudikoff et al., (1982) “Single amino acid substitution altering antigen-binding specificity,” PNAS, 79:1979-1983. [cited by applicant]
Sarkar et al., (2002) “Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching,” Nature Biotech. 20:908-913. [cited by applicant]
Sasaki et al., (2006) “Canonical NF-x13 Activity, Dispensable for B Cell Development, Replaces BAFF-Receptor Signals and Promotes B Cell Proliferation upon Activation,” Immunity, 24:729-739. [cited by applicant]
Schroeder et al., (2010) Genetic control of D [cited by applicant]
Schroeder et al., (2006) “Similarity and divergence in the development and expression of the mouse and human antibody repertoires,” Developmental and Comparative Immunol. 30(1-2):119-135. [cited by applicant]
Scott, (2007) “Mice with a human touch,” Nature Biotechnology, 25(10): 1075-1077. [cited by applicant]
Seals et al., (2003) “the ADAMs family of metalloproteases: multidomain; proteins with multiple functions,” Genes and Development, 17(1):7-30. [cited by applicant]
Sharpe et al., (1991) “Somatic hypermutation of immunoglobulin kappa may depend on sequences 3′ of C kappa and occurs on passenger transgenes,” EMBO J., 10(8):2139-2145. [cited by applicant]
Shriner et al., (2006) “Comparison of the human immune response to conjugate and polysaccharide pneumococcal vaccination using a reconstituted SCID mouse model,” Vaccine, 24:7197-7203. [cited by applicant]
Shriner et al., (2006) “Immunoglobulin light chain variable region, partial ( [cited by applicant]
Simister et al., (1989) An Fc receptor structurally related to MHC class I antigens, Nature 337:184-187. [cited by applicant]
Simon and Rajewsky, (1990), “Antibody domain mutants demonstrate autonomy of the antigen binding site,” EMBO J., 9(4):1051-1056. [cited by applicant]
Singer et al. (1998) “Genes and genomes,” Moscow, “Mir” 1:63-64 (English translation). [cited by applicant]
Sirac et al., (2006) “Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome,” Blood, 108(2):536-543. [cited by applicant]
Sirac et al. (2011) “Toward Understanding Renal Fanconi Syndrome: Step by Step Advances through Experimental Models,” Exp. Models for Renal Diseases: Pathogenesis and Diagnosis, Contrib. Nephrol. Basel, Karger, 169:247-… [cited by applicant]
Smith et al., (2010) “The unique and immunoglobulin-like regions of surrogate light chain component lambda5 differentially interrogate immunoglobulin heavy-chain structure,” Mol. Immunol., 47:1195-1206. [cited by applicant]
Soriano, (1999) “Generalized lacZ expression with the ROSA26 Cre reporter strain,” Nat. Genet., 21(1):70-71. [cited by applicant]
Stevens et al. (2006) “Velocimmune: Humanization of Immunoglobulin Loc Using Velocigene Technology,” First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2016—Athens, Greece… [cited by applicant]
Stevens et al., (2008) “Human Antibody Discovery, VelocImmune—A novel platform, Pharma Focus Asia,” Issue 8:72-74. [cited by applicant]
Storb et al., (1986) “Transgenic Mice with μ and κ Genes Encoding Antiphosphorycholine Antibodies”, J. Exp. Med., 164:627-641. [cited by applicant]
Suzuki et al., (2010) “Importance of Neonatal FcR in REgulation the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fus… [cited by applicant]
Tabrizi et al., (2006) “Elimination mechanisms of therapeutic monoclonal antibodies,” Drugs Discovery Today 11(1/2):81-88. [cited by applicant]
Taylor et al., (1992) “A Transgenic Mouse that Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins,” Nucleic Acid Research, 20(23):6287-6295. [cited by applicant]
Taylor et al., (1993) “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,” Int. Immunol. 6:579-591. [cited by applicant]
Tiegs et al. (1993) “Receptor Editing in Self-reactive Bone Marrow B Cells,” J. Exp. Med., 177:1009-1020. [cited by applicant]
Torres and Kuhn, (1997) “Laboratory Protocols for Conditional Gene Targeting,” Oxford University Press, 978-0-19-963677-8, 42-53. [cited by applicant]
Tsubata et al., (1990) “The Products of the Pre-B Cell-specific Genes (Lambda5 and VpreB) and the Immunoglobulin mu Chain Form a Comples that is Transported onto the Cell Surface,” J. Exp. Med., 172:973-976. [cited by applicant]
Tuaillon et al., (1995) “Analysis of direct and inverted DJH rearrangements in a human Ig heavy chain transgenic minilocus,” J. Immunol., 154(12):6453-6465. [cited by applicant]
Tutt et al., (1991) “Trispecific F(ab′)3 Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” J. Immunol. 147(1):60-69. [cited by applicant]
Tzaban et al., (2009) “The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity,” J. Cell Biol. 185(4):673-684. [cited by applicant]
Uson et al., (1997) “X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilized immunoglobulin variable domain,” Folding & Design, 2(6):357-361. [cited by applicant]
Valenzuela et al., (2003) “High-throughput engineering of the mouse genome coupled with high-resolution expression analysis,” Nature Biotech. 21(6):652-659. [cited by applicant]
Vaughn and Bjorkman, (1998) “Structural basis of pH-dependent antibody binding by the neonatal receptor,” Structure 6:63-73. [cited by applicant]
Vaughan et al., (1996) “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nat. Biotechnol., 14(3):309-314. [cited by applicant]
Wang, X. et al., Ab-origin: an enhanced tool to identify the sourcing gene segments in germline for rearranged antibodies. BMC Bioinformatics, 9(Suppl 12), 9 pages (2008). [cited by applicant]
Wang et al., (2008) “Monoclonal Antibody Pharmacokinetics and Pharmacodynamics,” Clinical Pharmacology & Therapeutics, 84(5):548-558. [cited by applicant]
Watanabe et al., (2009) “Optimizing pH Response of Affinity between Protein G and IgG Fc: How Electrostatic Modulations Affect Protein-Protein Interactions,” J. Biol. Chem. 284(18):12373-12383. [cited by applicant]
Winter et al., (1997) “Insertion of 2 kb of bacteriophage DNA between an immunoglobulin promoter and leader exon stops somatic hypermutaion in a kappa transgene,” Mol. Immunol., 34(5):359-366. [cited by applicant]
Xu and Davis (2000) “Diversity in the CDR3 Region of V [cited by applicant]
Xu et al., (2008) “Combinatorial surrobody libraries,” PNAS, 105(31):10756-10761. [cited by applicant]
Yeung et al., (2009) “Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates,” J. Immunol. 182(12):7663-7671. [cited by applicant]
Zhou et al., (2009) “Developing tTA transgenic rats for inducible and reversible gene expression,” International Journal of Biological Sciences, 5:171-181. [cited by applicant]
Chinese Search Report for related Chinese Application No. 201180013714.0, mailed May 15, 2013. [cited by applicant]
European Communication for Application No. 12 173 456.0 mailed Dec. 5, 2012. [cited by applicant]
European Examination for Application No. 11 703 799.4 mailed Oct. 9, 2012. [cited by applicant]
European Search Report for Application No. 12 173 456.0 dated Aug. 10, 2012. [cited by applicant]
Extended European Search Report with respect to EP Application No. 18158960.7, mailed Sep. 4, 2018. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2011/023971 mailed Apr. 11, 2011. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2012/034737 mailed Dec. 6, 2012. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2012/049600 mailed Nov. 23, 2012. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2013/029125 mailed Jun. 20, 2013. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2013/044257 mailed Sep. 4, 2013 (9 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2013/031823 mailed Jul. 8, 2013. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2013/031834 mailed Jul. 2, 2013. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2013/032036 mailed Jul. 1, 2013. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2014/025982 mailed Jul. 22, 2014 (13 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2014/026040 mailed Jul. 29, 2014, (14 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2014/056285 mailed Feb. 2, 2015. [cited by applicant]
Notice of Allowance with Respect to U.S. Appl. No. 13/832,309, Mailed Nov. 17, 2015. [cited by applicant]
Notice of Allowance with Respect to U.S. Appl. No. 13/832,247, Mailed Jan. 13, 2016. [cited by applicant]
Notice of Allowance with Respect to U.S. Appl. No. 14/705,916, Mailed Jan. 7, 2016. [cited by applicant]
Declaration 1.132 by Inventor Babb, Submitted with Respect to U.S. Appl. No. 13/832,309 on Oct. 13, 2015. [cited by applicant]
Declaration of Professor Dr. Roland Kontermann, Ph.D. for EP2505654 B1, 4 pages (May 19, 2017). [cited by applicant]
Declaration of Professor Michel Cogné, 26 pages (Jul. 17, 2017). [cited by applicant]
Notice of Opposition in EP2505654, 39 pages (May 24, 2017). [cited by applicant]
Opponent Reply to Patentee Submissions in EP2501817, 5 pages (Mar. 17, 2017). [cited by applicant]
Patent Oppositions—Decision in for AU2009263082, 53 pages (May 5, 2017). [cited by applicant]
Response to Opposition in EP2701499, 22 pages (Apr. 28, 2017). [cited by applicant]
Statement of Grounds of Appeal for Patent No. 2147594, 82 pages (2017). [cited by applicant]
Summons to Opposition in EP2501817, 12 pages (May 17, 2017). [cited by applicant]
Statement of Relatedness with Respect to U.S. Application No. to be assigned under MPEP 2001.06 dated Dec. 8, 2021. [cited by applicant]